Nichols Kristen, Girotto Jennifer, Steele Amy Mitchell-Van, Stoffella Sylvia
J Pediatr Pharmacol Ther. 2017 Jan-Feb;22(1):74-76. doi: 10.5863/1551-6776-22.1.74.
Despite the excellent benefit-to-risk ratio for human papillomavirus (HPV) vaccination and recommendations for its routine use from the Advisory Committee on Immunization Practices (ACIP), significant controversy surrounding HPV vaccination continues to exist. In light of this controversy and continued low rates of vaccination among U.S. adolescents, the Pediatric Pharmacy Advocacy Group (PPAG) endorses the safety and efficacy of HPV vaccination and agrees with ACIP recommendations for protection of the U.S. population against the potentially severe consequences of HPV. The PPAG recommends that all eligible individuals undergo vaccination. We further recommend that pediatric pharmacists participate in the education of patients and their families and serve as advocates for HPV vaccination. This document serves as an update to the 2008 PPAG position statement.1.
尽管人乳头瘤病毒(HPV)疫苗具有出色的效益风险比,且免疫实践咨询委员会(ACIP)也建议常规使用该疫苗,但围绕HPV疫苗接种的重大争议依然存在。鉴于这一争议以及美国青少年中持续较低的疫苗接种率,儿科药学倡导组织(PPAG)认可HPV疫苗接种的安全性和有效性,并赞同ACIP关于保护美国人群免受HPV潜在严重后果影响的建议。PPAG建议所有符合条件的个体都接种疫苗。我们还建议儿科药剂师参与对患者及其家属的教育,并充当HPV疫苗接种的倡导者。本文件是对2008年PPAG立场声明的更新。